Analyst Ratings for Roivant Sciences (ROIV) [Buys]
ROIV Rating Summary
ROIV Price Target Summary
- Highest: $15.00 (Truist Securities)
- Lowest: $6.00 (SVB Leerink)
- Average: $12.29
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$12.29 (+211%)
* Over Last 12-Mos
Rating Score: 8.8 / 10
Percentile Rank: 87%
Avg. $ Target:
$12.29 (+211%)
* Over Last 12-Mos
Rating Score: 8.8 / 10
Percentile Rank: 87%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/29/2022 | Cantor Fitzgerald » Updated 5/24/2022 |
Louise Chen | New Coverage | Overweight (N/A) |
15.00 (N/A) |
3.86 (3.95) |
2.33% | Details |
| 12/15/2021 | Goldman Sachs | Corinne Jenkins | New Coverage | Buy (N/A) |
15.00 (N/A) |
8.26 (3.95) |
-52.18% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
ROIV Ratings News
- "Continue to See Vtama’s Profile as Truly Differentiated" - Truist Securities Bullish on Roivant Sciences (ROIV) with $15 Price Target
- "VTAMA Has Blockbuster Potential" - Cantor Fitzgerald Bullish on Roivant Sciences (ROIV) Following Dermavant’s Drug Approval
- SVB Leerink Starts Roivant Sciences (ROIV) at Market Perform
- See More
